Bifurcation analysis of insulin regulated mTOR signalling pathway in cancer cells

Insulin induced mTOR signalling pathway is a complex network implicated in many types of cancers. The molecular mechanism of this pathway is highly complex and the dynamics is tightly regulated by intricate positive and negative feedback loops. In breast cancer cell lines, metformin has been shown to induce phosphorylation at specific serine sites in insulin regulated substrate of mTOR pathway that results in apoptosis over cell proliferation. The author models and performs bifurcation analysis to simulate cell proliferation and apoptosis in mTOR signalling pathway to capture the dynamics both in the presence and absence of metformin in cancer cells. Metformin is shown to negatively regulate PI3K through AMPK induced IRS1 phosphorylation and this brings about a reversal of AKT bistablity in codimension‐1 bifurcation diagram from S‐shaped, related to cell proliferation in the absence of drug metformin, to Z‐shaped, related to apoptosis in the presence of drug metformin. The author hypothesises and explains how this negative regulation acts a circuit breaker, as a result of which mTOR network favours apoptosis of cancer cells over its proliferation. The implication of reversing the shape of bistable dynamics from S to Z or vice‐versa in biological networks in general is discussed.Inspec keywords: bifurcation, molecular biophysics, drugs, enzymes, biochemistry, cellular biophysics, cancer, biomedical materialsOther keywords: intricate positive feedback loops, negative feedback loops, breast cancer cell lines, insulin regulated substrate, cell proliferation, cancer cells, AMPK induced IRS1 phosphorylation, codimension‐1 bifurcation diagram, drug metformin, mTOR network, insulin regulated mTOR signalling pathway, bifurcation analysis, PI3K, AKT bistablity     

Discovery of significant pathways in breast cancer metastasis via module extraction and comparison

Discovering significant pathways rather than single genes or small gene sets involved in metastasis is becoming more and more important in the study of breast cancer. Many researches have shed light on this problem. However, most of the existing works are relying on some priori biological information, which may bring bias to the models. The authors propose a new method that detects metastasis‐related pathways by identifying and comparing modules in metastasis and non‐metastasis gene co‐expression networks. The gene co‐expression networks are built by Pearson correlation coefficients, and then the modules inferred in these two networks are compared. In metastasis and non‐metastasis networks, 36 and 41 significant modules are identified. Also, 27.8% (metastasis) and 29.3% (non‐metastasis) of the modules are enriched significantly for one or several pathways with p ‐value <0.05. Many breast cancer genes including RB1, CCND1 and TP53 are included in these identified pathways. Five significant pathways are discovered only in metastasis network: glycolysis pathway, cell adhesion molecules, focal adhesion, stathmin and breast cancer resistance to antimicrotubule agents, and cytosolic DNA‐sensing pathway. The first three pathways have been proved to be closely associated with metastasis. The rest two can be taken as a guide for future research in breast cancer metastasis.Inspec keywords: cancer, genetics, genomics, DNA, molecular biophysics, adhesion, cellular biophysicsOther keywords: breast cancer metastasis, module extraction, gene sets, metastasis‐related pathways, nonmetastasis gene coexpression networks, Pearson correlation coefflcients, breast cancer genes, RB1, CCND1, TP53, glycolysis pathway, cell adhesion molecules, focal adhesion, stathmin, breast cancer resistance, antimicrotubule agents, cytosolic DNA‐sensing pathway, breast cancer metastasis     

Comprehensive study of tumour single nucleotide polymorphism array data reveals significant driver aberrations and disrupted signalling pathways in human hepatocellular cancer

The authors describe an integrated method for analysing cancer driver aberrations and disrupted pathways by using tumour single nucleotide polymorphism (SNP) arrays. The authors new method adopts a novel statistical model to explicitly quantify the SNP signals, and therefore infers the genomic aberrations, including copy number alteration and loss of heterozygosity. Examination on the dilution series dataset shows that this method can correctly identify the genomic aberrations even with the existence of severe normal cell contamination in tumour sample. Furthermore, with the results of the aberration identification obtained from multiple tumour samples, a permutation‐based approach is proposed for identifying the statistically significant driver aberrations, which are further incorporated with the known signalling pathways for pathway enrichment analysis. By applying the approach to 286 hepatocellular tumour samples, they successfully uncover numerous driver aberration regions across the cancer genome, for example, chromosomes 4p and 5q, which harbour many known hepatocellular cancer related genes such as alpha‐fetoprotein (AFP) and ectodermal‐neural cortex (ENC1). In addition, they identify nine disrupted pathways that are highly enriched by the driver aberrations, including the systemic lupus erythematosus pathway, the vascular endothelial growth factor (VEGF) signalling pathway and so on. These results support the feasibility and the utility of the proposed method on the characterisation of the cancer genome and the downstream analysis of the driver aberrations and the disrupted signalling pathways.Inspec keywords: cancer, DNA, genetics, genomics, liver, molecular biophysics, molecular configurations, physiological models, polymorphism, statistical analysis, tumoursOther keywords: tumour single nucleotide polymorphism array data, disrupted signalling pathways, human hepatocellular cancer, cancer driver aberrations, statistical model, SNP signals, genomic aberrations, heterozygosity, dilution series dataset, normal cell contamination, permutation‐based approach, statistical significant driver aberrations, hepatocellular tumour samples, cancer genome, hepatocellular cancer related genes, systemic lupus erythematosus pathway, VEGF signalling pathway     

In silico identification of potential targets and drugs for non‐small cell lung cancer

Lung cancer is one of the leading causes of death in both the USA and Taiwan, and it is thought that the cause of cancer could be because of the gain of function of an oncoprotein or the loss of function of a tumour suppressor protein. Consequently, these proteins are potential targets for drugs. In this study, differentially expressed genes are identified, via an expression dataset generated from lung adenocarcinoma tumour and adjacent non‐tumour tissues. This study has integrated many complementary resources, that is, microarray, protein‐protein interaction and protein complex. After constructing the lung cancer protein‐protein interaction network (PPIN), the authors performed graph theory analysis of PPIN. Highly dense modules are identified, which are potential cancer‐associated protein complexes. Up‐ and down‐regulated communities were used as queries to perform functional enrichment analysis. Enriched biological processes and pathways are determined. These sets of up‐ and down‐regulated genes were submitted to the Connectivity Map web resource to identify potential drugs. The authors'' findings suggested that eight drugs from DrugBank and three drugs from NCBI can potentially reverse certain up‐ and down‐regulated genes'' expression. In conclusion, this study provides a systematic strategy to discover potential drugs and target genes for lung cancer.Inspec keywords: cellular biophysics, lung, cancer, drugs, genetics, tumours, lab‐on‐a‐chip, proteins, molecular biophysics, graph theory, query processing, medical computingOther keywords: down‐regulated gene expression, up‐regulated gene expression, potential target genes, DrugBank, potential drugs, connectivity map Web resource, biological processes, functional enrichment analysis, up‐regulated communities, down‐regulated communities, cancer‐associated protein complexes, k‐communities, highly‐dense modules, PPIN, graph theory analysis, lung cancer protein‐protein interaction network, MIPS, BioGrid, ArrayExpress, microarray, nontumour tissues, human lung adenocarcinoma tumour, bioconductor package, tumour suppressor protein, oncoprotein, nonsmall cell lung cancer, in silico identification     

Classification of drug molecules for oxidative stress signalling pathway

In humans, oxidative stress is involved in the development of diabetes, cancer, hypertension, Alzheimers’ disease, and heart failure. One of the mechanisms in the cellular defence against oxidative stress is the activation of the Nrf2‐antioxidant response element (ARE) signalling pathway. Computation of activity, efficacy, and potency score of ARE signalling pathway and to propose a multi‐level prediction scheme for the same is the main aim of the study as it contributes in a big amount to the improvement of oxidative stress in humans. Applying the process of knowledge discovery from data, required knowledge is gathered and then machine learning techniques are applied to propose a multi‐level scheme. The validation of the proposed scheme is done using the K‐fold cross‐validation method and an accuracy of 90% is achieved for prediction of activity score for ARE molecules which determine their power to refine oxidative stress.Inspec keywords: cancer, cellular biophysics, biochemistry, drugs, molecular biophysics, proteins, learning (artificial intelligence), medical computingOther keywords: oxidative stress, Nrf2‐antioxidant response element signalling pathway, ARE signalling pathway, diabetes, cancer, hypertension, Alzheimers’ disease, heart failure, machine learning techniques, K‐fold cross‐validation method, ARE molecules     

Identification of specific microRNA–messenger RNA regulation pairs in four subtypes of breast cancer

Four subtypes of breast cancer, luminal A, luminal B, basal‐like, human epidermal growth factor receptor‐enriched, have been identified based on gene expression profiles of human tumours. The goal of this study is to find whether the same groups'' genes would exhibit different networks among the four subtypes. Differential expressed genes between each of the four subtypes and the normal samples were identified. The overlaps between the four groups of differentially expressed genes were used to construct regulations networks for each of the four subtypes. Univariate and multivariate Cox regressions were employed to test the genes in the four regulation networks. This study demonstrated that the common genes in four subtypes showed different regulation. Also, the hsa‐miR‐182 and decorin pair performs different functions among the four subtypes of breast cancer. The result indicated that heterogeneity of breast cancer is not only reflected in the different expression patterns among different genes, but also in the different regulatory networks of the same group of genes.Inspec keywords: genetics, cellular biophysics, tumours, molecular biophysics, RNA, biochemistry, cancer, proteins, biology computingOther keywords: decorin pair performs different functions, breast cancer heterogeneity, regulatory networks, specific microRNA–messenger, regulation pairs, human epidermal growth factor receptor, gene expression profiles, differentially expressed genes, regulations networks, hsa‐miR‐182, decorin pair, human tumours     

Adaptive non‐linear control for cancer therapy through a Fokker–Planck observer

In recent years, many efforts have been made to present optimal strategies for cancer therapy through the mathematical modelling of tumour‐cell population dynamics and optimal control theory. In many cases, therapy effect is included in the drift term of the stochastic Gompertz model. By fitting the model with empirical data, the parameters of therapy function are estimated. The reported research works have not presented any algorithm to determine the optimal parameters of therapy function. In this study, a logarithmic therapy function is entered in the drift term of the Gompertz model. Using the proposed control algorithm, the therapy function parameters are predicted and adaptively adjusted. To control the growth of tumour‐cell population, its moments must be manipulated. This study employs the probability density function (PDF) control approach because of its ability to control all the process moments. A Fokker–Planck‐based non‐linear stochastic observer will be used to determine the PDF of the process. A cost function based on the difference between a predefined desired PDF and PDF of tumour‐cell population is defined. Using the proposed algorithm, the therapy function parameters are adjusted in such a manner that the cost function is minimised. The existence of an optimal therapy function is also proved. The numerical results are finally given to demonstrate the effectiveness of the proposed method.Inspec keywords: physiological models, cancer, patient treatment, probability, stochastic processes, tumours, Fokker‐Planck equation, statistical analysis, cellular biophysicsOther keywords: adaptive nonlinear control, cancer therapy, Fokker‐Planck observer, tumour cell growth behavior, mathematical modelling, tumour‐cell population dynamics, optimal control theory, stochastic Gompertz model, empirical data, statistical methods, logarithmic function, probability density function, nonlinear stochastic observer     

Emerging microfluidic devices for cancer cells/biomarkers manipulation and detection

Circulating tumour cells (CTCs) are active participants in the metastasis process and account for ∼90% of all cancer deaths. As CTCs are admixed with a very large amount of erythrocytes, leukocytes, and platelets in blood, CTCs are very rare, making their isolation, capture, and detection a major technological challenge. Microfluidic technologies have opened‐up new opportunities for the screening of blood samples and the detection of CTCs or other important cancer biomarker‐proteins. In this study, the authors have reviewed the most recent developments in microfluidic devices for cells/biomarkers manipulation and detection, focusing their attention on immunomagnetic‐affinity‐based devices, dielectrophoresis‐based devices, surface‐plasmon‐resonance microfluidic sensors, and quantum‐dots‐based sensors.Inspec keywords: microfluidics, bioMEMS, cancer, cellular biophysics, biomedical equipment, patient diagnosis, tumours, proteins, molecular biophysics, electrophoresis, surface plasmon resonance, quantum dotsOther keywords: quantum‐dot‐based sensors, surface‐plasmon‐resonance microfluidic sensors, dielectrophoresis‐based devices, immunomagnetic‐affinity‐based devices, cancer biomarker‐proteins, CTC detection, blood samples, microfluidic technology, platelets, leukocytes, leukocytes, erythrocytes, cancer deaths, metastasis process, circulating tumour cells, cancer cell‐biomarker detection, cancer cell‐biomarker manipulation, microfluidic devices     

Identification and analysis of circRNA–miRNA–mRNA regulatory network in hepatocellular carcinoma

This study was to identify important circRNA–miRNA–mRNA (ceRNAs) regulatory mechanisms in hepatocellular carcinoma (HCC). The circRNA dataset {"type":"entrez-geo","attrs":{"text":"GSE97332","term_id":"97332"}}GSE97332 and miRNA dataset {"type":"entrez-geo","attrs":{"text":"GSE57555","term_id":"57555"}}GSE57555 were used for analyses. Functional enrichment analysis for miRNA and target gene was conducted using cluster Profiler. Survival analysis was conducted through R package Survival. The ceRNAs and drug–gene interaction networks were constructed. The ceRNAs network contained five miRNAs including hsa‐miR‐25‐3p, hsa‐miR‐3692‐5p, hsa‐miR‐4270, hsa‐miR‐331‐3p, and hsa‐miR‐125a‐3p. Among the network, hsa‐miR‐25‐3p targeted the most genes, hsa‐miR‐3692‐5p and hsa‐miR‐4270 were targeted by more circRNAs than other miRNAs, hsa‐circ‐0034326 and hsa‐circ‐0011950 interacted with three miRNAs. Furthermore, target genes, including NRAS, ITGA5, SLC7A1, SEC14L2, SLC12A5, and SMAD2 were obtained in drug–gene interaction network. Survival analysis showed NRAS, ITGA5, SLC7A1, SEC14L2, SLC12A5, and SMAD2 were significantly associated with prognosis of HCC. NRAS, ITGA5, and SMAD2 were significantly enriched in proteoglycans in cancer. Moreover, hsa‐circ‐0034326 and hsa‐circ‐0011950 might function as ceRNAs to play key roles in HCC. Furthermore, miR‐25‐3p, miR‐3692‐5p, and miR‐4270 might be significant for HCC development. NRAS, ITGA5, SEC14L2, SLC12A5, and SMAD2 might be prognostic factors for HCC patients via proteoglycans in cancer pathway. Taken together, the findings will provide novel insight into pathogenesis, selection of therapeutic targets and prognostic factors for HCC.Inspec keywords: cancer, cellular biophysics, patient diagnosis, bioinformatics, tumours, biochemistry, molecular biophysics, genetics, drugs, RNAOther keywords: ITGA5, SMAD2, hsa‐circ‐0034326, SEC14L2, SLC12A5, target gene, survival analysis, drug–gene interaction network, miRNAs, hsa‐miR‐25‐3p, hsa‐miR‐3692‐5p, hsa‐miR‐4270, hsa‐miR‐331‐3p, hsa‐miR‐125a‐3p, hsa‐circ‐0011950, SLC7A1, pathogenesis, therapeutic targets, prognostic factors, circRNA‐miRNA‐mRNA regulatory network, current 125.0 A     

siRNA nanotherapeutics: a promising strategy for anti‐HBV therapy

Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) and liver cirrhosis worldwide. In spite of the numerous advances in the treatment of CHB, drugs and vaccines have failed because of many factors like complexity, resistance, toxicity, and heavy cost. New RNA interference (RNAi)‐based technologies have developed innovative strategies to target Achilles'' heel of the several hazardous diseases involving cancer, some genetic disease, autoimmune illnesses, and viral disorders particularly hepatitis B virus (HBV) infections. Naked siRNA delivery has serious challenges including failure to cross the cell membrane, susceptibility to the enzymatic digestion, and excretion by renal filtration, which ideally can be addressed by nanoparticle‐mediated delivery systems. cccDNA formation is a significant problem in obtaining HBV infections complete cure because of strength, durability, and lack of proper immune response. Nano‐siRNA drugs have a great potential to address this problem by silencing specific genes which are involved in cccDNA formation. In this article, the authors describe siRNA nanocarrier‐mediated delivery systems as a promising new strategy for HBV infections therapy. Simultaneously, the authors completely represent the clinical trials which use these strategies for treatment of the HBV infections.Inspec keywords: tumours, drugs, genetics, cellular biophysics, RNA, nanomedicine, diseases, molecular biophysics, microorganisms, cancer, liver, nanoparticles, patient treatmentOther keywords: siRNA nanotherapeutics, anti‐HBV therapy, chronic hepatitis B, CHB, HCC, hazardous diseases, cancer, genetic disease, autoimmune illnesses, viral disorders, hepatitis B virus infections, naked siRNA delivery, cell membrane, enzymatic digestion, renal filtration, nanoparticle‐mediated delivery systems, cccDNA formation, HBV infections complete cure, nanosiRNA drugs, siRNA nanocarrier‐mediated delivery systems, HBV infections therapy, liver cirrhosis, RNA interference, immune response, hepatocellular carcinoma     

Identify signature regulatory network for glioblastoma prognosis by integrative mRNA and miRNA co‐expression analysis

Glioblastoma multiforme (GBM) is the most common and aggressive type of primary brain tumor in adults. Patients with this disease have a poor prognosis. The objective of this study is to identify survival‐related individual genes (or miRNAs) and miRNA ‐mRNA pairs in GBM using a multi‐step approach. First, the weighted gene co‐expression network analysis and survival analysis are applied to identify survival‐related modules from mRNA and miRNA expression profiles, respectively. Subsequently, the role of individual genes (or miRNAs) within these modules in GBM prognosis are highlighted using survival analysis. Finally, the integration analysis of miRNA and mRNA expression as well as miRNA target prediction is used to identify survival‐related miRNA ‐mRNA regulatory network. In this study, five genes and two miRNA modules that significantly correlated to patient''s survival. In addition, many individual genes (or miRNAs) assigned to these modules were found to be closely linked with survival. For instance, increased expression of neuropilin‐1 gene (a member of module turquoise) indicated poor prognosis for patients and a group of miRNA ‐mRNA regulatory networks that comprised 38 survival‐related miRNA ‐mRNA pairs. These findings provide a new insight into the underlying molecular regulatory mechanisms of GBM.Inspec keywords: RNA, molecular biophysics, genetics, cancerOther keywords: signature regulatory network, glioblastoma prognosis, mRNA coexpression analysis, miRNA coexpression analysis, glioblastoma multiforme, brain tumour, microRNAs, pathogenesis, genome‐wide regulatory networks, miRNA‐mRNA pairs, weighted gene coexpression network analysis, survival analysis, GBM prognosis, integration analysis, neuropilin‐1 gene, module turquoise, molecular regulatory mechanisms     

Ensembled machine learning framework for drug sensitivity prediction

Drug sensitivity prediction is one of the critical tasks involved in drug designing and discovery. Recently several online databases and consortiums have contributed to providing open access to pharmacogenomic data. These databases have helped in developing computational approaches for drug sensitivity prediction. Cancer is a complex disease involving the heterogeneous behaviour of same tumour‐type patients towards the same kind of drug therapy. Several methods have been proposed in the literature to predict drug sensitivity. However, these methods are not efficient enough to predict drug sensitivity. The present study has proposed an ensemble learning framework for drug‐response prediction using a modified rotation forest. The proposed framework is further compared with three state‐of‐the‐art algorithms and two baseline methods using Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE) drug screens. The authors have also predicted missing drug response values in the data set using the proposed approach. The proposed approach outperforms other counterparts even though gene mutation data is not incorporated while designing the approach. An average mean square error of 3.14 and 0.404 is achieved using GDSC and CCLE drug screens, respectively. The obtained results show that the proposed framework has considerable potential to improve anti‐cancer drug response prediction.Inspec keywords: medical computing, molecular biophysics, genomics, genetics, learning (artificial intelligence), patient treatment, drugs, cellular biophysics, cancer, biology computing, tumours, diseasesOther keywords: ensembled machine learning framework, drug sensitivity prediction, drug therapy, ensemble learning framework, drug‐response prediction, Cancer Cell Line Encyclopedia drug screens, drug response values, CCLE drug screens, anti‐cancer drug response prediction     

Mining gene link information for survival pathway hunting

This study proposes a gene link‐based method for survival time‐related pathway hunting. In this method, the authors incorporate gene link information to estimate how a pathway is associated with cancer patient''s survival time. Specifically, a gene link‐based Cox proportional hazard model (Link‐Cox) is established, in which two linked genes are considered together to represent a link variable and the association of the link with survival time is assessed using Cox proportional hazard model. On the basis of the Link‐Cox model, the authors formulate a new statistic for measuring the association of a pathway with survival time of cancer patients, referred to as pathway survival score (PSS), by summarising survival significance over all the gene links in the pathway, and devise a permutation test to test the significance of an observed PSS. To evaluate the proposed method, the authors applied it to simulation data and two publicly available real‐world gene expression data sets. Extensive comparisons with previous methods show the effectiveness and efficiency of the proposed method for survival pathway hunting.Inspec keywords: cancer, physiological models, bioinformatics, genomicsOther keywords: permutation test, pathway survival score, gene link‐based Cox proportional hazard model, cancer patient survival time, survival time‐related pathway hunting, gene link‐based method     

Gaussian graphical model for identifying significantly responsive regulatory networks from time course high‐throughput data

With rapid accumulation of functional relationships between biological molecules, knowledge‐based networks have been constructed and stocked in many databases. These networks provide curated and comprehensive information for functional linkages among genes and proteins, whereas their activities are highly related with specific phenotypes and conditions. To evaluate a knowledge‐based network in a specific condition, the consistency between its structure and conditionally specific gene expression profiling data are an important criterion. In this study, the authors propose a Gaussian graphical model to evaluate the documented regulatory networks by the consistency between network architectures and time course gene expression profiles. They derive a dynamic Bayesian network model to evaluate gene regulatory networks in both simulated and true time course microarray data. The regulatory networks are evaluated by matching network structure with gene expression to achieve consistency measurement. To demonstrate the effectiveness of the authors method, they identify significant regulatory networks in response to the time course of circadian rhythm. The knowledge‐based networks are screened and ranked by their structural consistencies with dynamic gene expression profiling.Inspec keywords: Bayes methods, biology computing, circadian rhythms, Gaussian processes, genetics, genomics, graphs, molecular biophysics, proteinsOther keywords: Gaussian graphical model, responsive regulatory networks, time course high‐throughput data, biological molecules, dynamic gene expression proflling, circadian rhythm, consistency measurement, matching network structure, simulated time course microarray data, true time course microarray data, dynamic Bayesian network model, time course gene expression proflles, network architectures, documented regulatory networks, speciflc gene expression proflling data, phenotypes, proteins, functional linkages, databases, knowledge‐based networks     

Revealing determinants of two‐phase dynamics of P53 network under gamma irradiation based on a reduced 2D relaxation oscillator model

This study proposes a two‐dimensional (2D) oscillator model of p53 network, which is derived via reducing the multidimensional two‐phase dynamics model into a model of ataxia telangiectasia mutated (ATM) and Wip1 variables, and studies the impact of p53‐regulators on cell fate decision. First, the authors identify a 6D core oscillator module, then reduce this module into a 2D oscillator model while preserving the qualitative behaviours. The introduced 2D model is shown to be an excitable relaxation oscillator. This oscillator provides a mechanism that leads diverse modes underpinning cell fate, each corresponding to a cell state. To investigate the effects of p53 inhibitors and the intrinsic time delay of Wip1 on the characteristics of oscillations, they introduce also a delay differential equation version of the 2D oscillator. They observe that the suppression of p53 inhibitors decreases the amplitudes of p53 oscillation, though the suppression increases the sustained level of p53. They identify Wip1 and P53DINP1 as possible targets for cancer therapies considering their impact on the oscillator, supported by biological findings. They model some mutations as critical changes of the phase space characteristics. Possible cancer therapeutic strategies are then proposed for preventing these mutations’ effects using the phase space approach.Inspec keywords: physiological models, cellular biophysics, cancer, difference equations, delays, enzymes, biochemistry, molecular biophysics, gamma‐rays, radiation therapyOther keywords: two‐phase dynamics model, P53 network, gamma irradiation, 2D relaxation oscillator model, ATM model, Wip1 variables, p53‐regulators, cell fate decision, excitable relaxation oscillator, Wip1 time delay, state‐dependent delay differential equation, cell cycle arrest, cell apoptosis, cancer therapies, Wip1 overexpression, Wip1 downregulation, ATM deficiency, Mdm2 overexpression, Mdm2 downregulation, mutation effects, phase space approach     

Network‐based method for detecting dysregulated pathways in glioblastoma cancer

The knowledge on the biological molecular mechanisms underlying cancer is important for the precise diagnosis and treatment of cancer patients. Detecting dysregulated pathways in cancer can provide insights into the mechanism of cancer and help to detect novel drug targets. Based on the wide existing mutual exclusivity among mutated genes and the interrelationship between gene mutations and expression changes, this study presents a network‐based method to detect the dysregulated pathways from gene mutations and expression data of the glioblastoma cancer. First, the authors construct a gene network based on mutual exclusivity between each pair of genes and the interaction between gene mutations and expression changes. Then they detect all complete subgraphs using CFinder clustering algorithm in the constructed gene network. Next, the two gene sets whose overlapping scores are above a specific threshold are merged. Finally, they obtain two dysregulated pathways in which there are glioblastoma‐related multiple genes which are closely related to the two subtypes of glioblastoma. The results show that one dysregulated pathway revolving around epidermal growth factor receptor is likely to be associated with the primary subtype of glioblastoma, and the other dysregulated pathway revolving around TP53 is likely to be associated with the secondary subtype of glioblastoma.Inspec keywords: cancer, tumours, drugs, brain, neurophysiology, genetic algorithms, genetics, skin, proteins, molecular biophysics, genomics, patient diagnosis, molecular configurationsOther keywords: network‐based method, dysregulated pathways detection, glioblastoma cancer, biological molecular mechanisms, precise diagnosis, cancer patient treatment, drug targets, mutual exclusivity, mutated genes, gene mutations, expression changes, expression data, CFinder clustering algorithm, constructed gene network, gene sets, overlapping scores, glioblastoma‐related multiple genes, epidermal growth factor receptor, TP53, secondary subtype     

Fold change based approach for identification of significant network markers in breast,lung and prostate cancer

Cancer belongs to a class of highly aggressive diseases and a leading cause of death in the world. With more than 100 types of cancers, breast, lung and prostate cancer remain to be the most common types. To identify essential network markers (NMs) and therapeutic targets in these cancers, the authors present a novel approach which uses gene expression data from microarray and RNA‐seq platforms and utilises the results from this data to evaluate protein–protein interaction (PPI) network. Differentially expressed genes (DEGs) are extracted from microarray data using three different statistical methods in R, to produce a consistent set of genes. Also, DEGs are extracted from RNA‐seq data for the same three cancer types. DEG sets found to be common in both platforms are obtained at three fold change (FC) cut‐off levels to accurately identify the level of change in expression of these genes in all three cancers. A cancer network is built using PPI data characterising gene sets at log‐FC (LFC)>1, LFC>1.5 and LFC>2, and interconnection between principal hub nodes of these networks is observed. Resulting network of hubs at three FC levels highlights prime NMs with high confidence in multiple cancers as validated by Gene Ontology functional enrichment and maximal complete subgraphs from CFinder.Inspec keywords: cancer, proteins, RNA, bioinformatics, statistical analysis, genetics, molecular biophysics, ontologies (artificial intelligence), lungOther keywords: cancer network, PPI data, gene sets, multiple cancers, Gene Ontology functional enrichment, prostate cancer, gene expression data, RNA‐seq platforms, protein–protein interaction network, DEG, microarray data, RNA‐seq data, cancer types, lung cancer, diseases, breast cancer, network markers, differentially expressed genes, fold change based approach, CFinder, statistical methods